Biofrontera AG announced that it has established a subsidiary to continue the commercialization of Ameluz® in the United Kingdom. The newly founded Biofrontera UK Ltd. Is based in Cambridge, UK and headed by Ms. Pilar de la Huerta and Dr. Montserrat Foguet as Managing Directors.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.085 EUR | -5.66% | -44.42% | -51.49% |
May. 15 | Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M | MT |
Apr. 30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.49% | 13.49M | |
+32.91% | 709B | |
+30.77% | 595B | |
-1.78% | 367B | |
+20.21% | 334B | |
+5.95% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+8.99% | 171B |
- Stock Market
- Equities
- B8FK Stock
- News Biofrontera AG
- Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd